Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Growth in Short Interest

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 4,110,000 shares, a growth of 9.9% from the March 31st total of 3,740,000 shares. Approximately 9.9% of the shares of the stock are sold short. Based on an average daily volume of 553,100 shares, the short-interest ratio is currently 7.4 days.

Structure Therapeutics Stock Performance

Shares of GPCR traded up $0.40 during mid-day trading on Tuesday, hitting $39.44. 707,077 shares of the stock were exchanged, compared to its average volume of 569,908. The company has a market cap of $1.84 billion and a PE ratio of -47.52. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02. The firm has a 50-day moving average of $39.44 and a two-hundred day moving average of $47.25.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. On average, sell-side analysts predict that Structure Therapeutics will post -0.98 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Lifesci Capital reiterated an "outperform" rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Thursday, April 18th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $85.71.

Institutional Trading of Structure Therapeutics

Several hedge funds have recently made changes to their positions in GPCR. Picton Mahoney Asset Management purchased a new stake in Structure Therapeutics during the third quarter valued at approximately $116,000. Sectoral Asset Management Inc. bought a new position in Structure Therapeutics during the fourth quarter valued at $139,000. ADAR1 Capital Management LLC purchased a new stake in shares of Structure Therapeutics in the fourth quarter valued at $163,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Structure Therapeutics by 208.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company's stock worth $177,000 after acquiring an additional 2,939 shares during the last quarter. Finally, Washington University bought a new position in Structure Therapeutics during the 3rd quarter valued at about $215,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.